Regeneron Pharmaceuticals Stock in Focus

By Scott Lee • Wednesday, June 28 09:44 • Permanent Link

Large-cap Health Care company Regeneron Pharmaceuticals has logged a -3.5% change today on a trading volume of 219,947. The average volume for the stock is 553,508.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Based in Tarrytown, United States the company has 12,099 full time employees and a market cap of $75,810,160,640.

The company is now trading -21.91% away from its average analyst target price of $884.86 per share. The 22 analysts following the stock have set target prices ranging from $650.0 to $1050.0, and on average give Regeneron Pharmaceuticals a rating of buy.

Over the last year, REGN shares have gone up 19.8%, which represents a difference of 5.0% when compared to the S&P 500. The stock's 52 week high is $837.55 per share whereas its 52 week low is $563.82. Based on Regeneron Pharmaceuticals's compounded average operating margin growth of 9.9% over the last 4 years, its core business remains strong and its strong stock performance may continue in the long term.

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.